Skip to Main Content

Paper Details

Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US.
J Med Econ
9
2022
Author NameAffiliation
Joshua N GoldsteinMassachusetts General Hospital
  • 1 - 1

Datasets

Release 1.2